ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 121 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $583,044 | -12.6% | 29,065 | +22.9% | 0.00% | 0.0% |
Q2 2023 | $667,054 | +71.2% | 23,646 | +4.4% | 0.00% | +33.3% |
Q1 2023 | $389,735 | -12.9% | 22,659 | +2.0% | 0.00% | 0.0% |
Q4 2022 | $447,269 | -7.4% | 22,208 | -0.4% | 0.00% | -25.0% |
Q3 2022 | $483,000 | -4.4% | 22,289 | +24.0% | 0.00% | +33.3% |
Q2 2022 | $505,000 | -39.5% | 17,982 | -0.7% | 0.00% | -40.0% |
Q1 2022 | $835,000 | -48.7% | 18,103 | -6.6% | 0.01% | -37.5% |
Q4 2021 | $1,629,000 | +24.4% | 19,379 | -1.4% | 0.01% | +14.3% |
Q3 2021 | $1,309,000 | +32.1% | 19,649 | +5.5% | 0.01% | +133.3% |
Q2 2021 | $991,000 | +36.3% | 18,630 | +11.2% | 0.00% | 0.0% |
Q1 2021 | $727,000 | -16.2% | 16,755 | +0.3% | 0.00% | 0.0% |
Q4 2020 | $868,000 | +285.8% | 16,711 | +142.5% | 0.00% | +200.0% |
Q3 2020 | $225,000 | -26.0% | 6,892 | +9.0% | 0.00% | 0.0% |
Q2 2020 | $304,000 | – | 6,323 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Decheng Capital Management III (Cayman), LLC | 1,824,583 | $39,520,000 | 14.33% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,301,771 | $49,857,000 | 4.79% |
Matrix Capital Management Company, LP | 9,199,973 | $199,271,000 | 3.81% |
Integral Health Asset Management, LLC | 550,000 | $11,913,000 | 2.31% |
Avidity Partners Management LP | 4,223,100 | $91,472,000 | 1.86% |
Affinity Asset Advisors, LLC | 170,000 | $3,682,000 | 1.03% |
Eventide Asset Management | 1,861,000 | $40,309,000 | 0.79% |
Sofinnova Investments, Inc. | 583,357 | $12,636,000 | 0.74% |
Nicholas Investment Partners, LP | 158,704 | $3,438,000 | 0.32% |
SECTORAL ASSET MANAGEMENT INC | 60,000 | $1,300,000 | 0.26% |